
USD
$0.00
(0.00%
)At Close (As of Nov 19, 2025)
$240.86B
Market Cap
12.76
P/E Ratio
7.56
EPS
$101.32
52 Week High
$71.87
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $49B |
| Total Revenue | $64B |
| Cost Of Revenue | $15B |
| Costof Goods And Services Sold | $15B |
| Operating Income | $20B |
| Selling General And Administrative | $7.7B |
| Research And Development | $18B |
| Operating Expenses | $29B |
| Investment Income Net | - |
| Net Interest Income | -$856M |
| Interest Income | $415M |
| Interest Expense | $1.3B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.5B |
| Income Before Tax | $20B |
| Income Tax Expense | $2.8B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $17B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $21B |
| Ebitda | $26B |
| Net Income | $17B |
| Field | Value (USD) |
|---|---|
| Total Assets | $117B |
| Total Current Assets | $39B |
| Cash And Cash Equivalents At Carrying Value | $13B |
| Cash And Short Term Investments | $13B |
| Inventory | $6.1B |
| Current Net Receivables | $10B |
| Total Non Current Assets | $78B |
| Property Plant Equipment | $25B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $16B |
| Intangible Assets Excluding Goodwill | $16B |
| Goodwill | $22B |
| Investments | - |
| Long Term Investments | $463M |
| Short Term Investments | $447M |
| Other Current Assets | $8.7B |
| Other Non Current Assets | - |
| Total Liabilities | $71B |
| Total Current Liabilities | $28B |
| Current Accounts Payable | $4.1B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.9B |
| Total Non Current Liabilities | $42B |
| Capital Lease Obligations | - |
| Long Term Debt | $34B |
| Current Long Term Debt | $2.6B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $38B |
| Other Current Liabilities | $17B |
| Other Non Current Liabilities | $6.5B |
| Total Shareholder Equity | $46B |
| Treasury Stock | - |
| Retained Earnings | $63B |
| Common Stock | $1.8B |
| Common Stock Shares Outstanding | $2.5B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $21B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $4.5B |
| Capital Expenditures | $3.4B |
| Change In Receivables | - |
| Change In Inventory | -$835M |
| Profit Loss | - |
| Cashflow From Investment | -$7.7B |
| Cashflow From Financing | -$7B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $7.8B |
| Dividend Payout Common Stock | $7.8B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$1.3B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $17B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $49B |
| Total Revenue | $64B |
| Cost Of Revenue | $15B |
| Costof Goods And Services Sold | $15B |
| Operating Income | $20B |
| Selling General And Administrative | $7.7B |
| Research And Development | $18B |
| Operating Expenses | $29B |
| Investment Income Net | - |
| Net Interest Income | -$856M |
| Interest Income | $415M |
| Interest Expense | $1.3B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $4.5B |
| Income Before Tax | $20B |
| Income Tax Expense | $2.8B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $17B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $21B |
| Ebitda | $26B |
| Net Income | $17B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-09-15 |
| Declaration Date | 2025-07-22 |
| Record Date | 2025-09-15 |
| Payment Date | 2025-10-07 |
| Amount | 0.81 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Merck & Company Inc. is a leading American multinational pharmaceutical corporation based in Kenilworth, New Jersey, renowned for its commitment to advancing global health through innovative pharmaceuticals and vaccines. Founded in 1891, the company has a distinguished history of scientific breakthroughs, primarily focusing on oncology, infectious diseases, and cardiovascular therapeutics. Merck maintains a strong clinical pipeline and invests heavily in research and development, solidifying its status as a frontrunner in the biopharmaceutical industry. With a dedication to improving patient outcomes and ensuring healthcare accessibility, Merck leverages its scientific expertise and strategic partnerships to navigate the dynamic healthcare landscape, positioning itself for sustained growth and innovation.